Morgan Stanley Red Hill Biopharma Ltd. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $695.9 $8,137 - $40.5 Million	58,128 Added 15.01%	445,309 $62,000
Q3 2022 Nov 14, 2022	BUY	$0.5 - $523.8 $121,479 - $127 Million	242,959 Added 168.46%	387,181 $195,000
Q2 2022 Oct 27, 2022	BUY	$0.63 - $2.58 $66,216 - $271,173	105,106 Added 268.7%	144,222 $125,000
Q2 2022 Aug 15, 2022	BUY	$0.63 - $2.58 $66,216 - $271,173	105,106 Added 268.7%	144,222 $125,000
Q1 2022 Oct 27, 2022	SELL	$1.65 - $3.12 $173,424 - $327,930	-105,106 Reduced 72.88%	39,116 $99,000
Q1 2022 May 13, 2022	BUY	$1.65 - $3.12 $5,933 - $11,219	3,596 Added 10.12%	39,116 $99,000
Q4 2021 Feb 14, 2022	BUY	$2.31 - $5.85 $3,416 - $8,652	1,479 Added 4.34%	35,520 $92,000
Q3 2021 Nov 15, 2021	BUY	$4.55 - $10.36 $154,886 - $352,664	34,041 New	34,041 $156,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $557M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.